相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease
Gil Y. Melmed et al.
ANNALS OF INTERNAL MEDICINE (2021)
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
Corey A. Siegel et al.
GUT (2021)
Neutralizing antibodies targeting SARS-CoV-2 spike protein
Shi Xiaojie et al.
STEM CELL RESEARCH (2021)
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
Serre-Yu Wong et al.
GASTROENTEROLOGY (2021)
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Nicholas A. Kennedy et al.
GUT (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury et al.
NATURE MEDICINE (2021)
Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
Fatema Alrashed et al.
BMJ OPEN GASTROENTEROLOGY (2021)
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 A Prospective Cohort Study
Parakkal Deepak et al.
ANNALS OF INTERNAL MEDICINE (2021)
BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign
Amir Ben-Tov et al.
GASTROENTEROLOGY (2021)
Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications
Nabeel Khan et al.
GASTROENTEROLOGY (2021)
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
Laith J. Abu-Raddad et al.
JOURNAL OF TRAVEL MEDICINE (2021)
ANTI-SPIKE S1 IGA, ANTI-SPIKE TRIMERIC IGG, AND ANTI-SPIKE RBD IGG RESPONSE AFTER BNT162B2 COVID-19 MRNA VACCINATION IN HEALTHCARE WORKERS
Gian Luca Salvagno et al.
JOURNAL OF MEDICAL BIOCHEMISTRY (2021)
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2020)
Management of Patients with Crohn’s Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting
David T. Rubin et al.
GASTROENTEROLOGY (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease
Fabio Salvatore Macaluso et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases
Julien Kirchgesner et al.
GASTROENTEROLOGY (2018)
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
Ulrike Billmeier et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
Tim Wyant et al.
GUT (2015)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
Erik von Elm et al.
INTERNATIONAL JOURNAL OF SURGERY (2014)
American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Jonathan P. Terdiman et al.
GASTROENTEROLOGY (2013)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)